Sultamisilin | 94935-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: Sultamisilin
• 英文别名: (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 94935-63-4
• 化学式: C24H30N4O9S2
• 分子量: 582.7
• InChiKey: XBKAJGGBQLRIFJ-OUPOZMNRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.48
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  238
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• INTRAVENOUS GANAXOLONE FORMULATIONS AND METHODS OF USE IN TREATING STATUS EPILEPTICUS AND OTHER SEIZURE DISORDERS
  申请人：MARINUS PHARMACEUTICALS, INC.

  公开号：US20160228454A1

  公开（公告）日：2016-08-11

  The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone/ sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone/ sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

  本公开提供了一种可注射的甘纳酮制剂，包括甘纳酮、磺基丁基醚-β-环糊精和水。该可注射的甘纳酮制剂可选包括表面活性剂和pH调节剂。甘纳酮和磺基丁基醚-β-环糊精可以形成包含复合物。本公开还提供了甘纳酮/磺基丁基醚-β-环糊精制剂的冻干粉末，可在注射用水中重组。本公开提供了一种治疗癫痫、中风或创伤性脑损伤患者的方法，包括给予有效量的可注射的甘纳酮制剂，包括甘纳酮、磺基丁基醚-β-环糊精和水。本公开还提供了联合使用方法，其中可注射的甘纳酮/磺基丁基醚-β-环糊精制剂与至少一种其他活性剂联合使用。
• Fluid component analysis system and method for glucose monitoring and control
  申请人：Optiscan Biomedical Corporation

  公开号：EP2695573A2

  公开（公告）日：2014-02-12

  An analyte detection and control system to determine and regulate the concentration of one or more analytes in a sample of bodily fluid is provided, which system comprises a control system; an analyte detector configured to measure a characteristic of at least one analyte in the sample of bodily fluid and determine a concentration of the analyte in the sample based on the measured characteristic; a fluid handling system operatively coupled to the analyte detector, said fluid handling system comprising a fluid passageway in communication with a patient through a patient end; a pump unit configured to engage the fluid handling system and draw a sample of bodily fluid from the patient periodically at draw intervals of less than 1 hour for analysis; a source of infusion fluid configured to adjust glycemic levels in the patient, said infusion fluid source in fluid communication with the fluid handling system; and a treatment dosing system in communication with the body fluid analyzer, said treatment dosing system including a treatment dosing protocol and configured to determine a recommended dose for the infusion fluid, wherein the recommended dose is determined based at least in part on one or more determinations by the body fluid analyzer of the concentration of the analyte and the treatment dosing protocol.

  提供了一种用于确定和调节体液样本中一种或多种分析物浓度的分析物检测和控制系统，该系统包括控制系统；分析物检测器，配置用于测量体液样本中至少一种分析物的特征，并根据测量的特征确定样本中分析物的浓度；流体处理系统，与分析物检测器操作性耦合，所述流体处理系统包括流体通道，通过患者端与患者通信；泵装置，配置为与流体处理系统连接，并以少于 1 小时的抽取间隔定期从患者体内抽取体液样本进行分析； 输液源，配置为调节患者体内的血糖水平，所述输液源与流体处理系统进行流体通信；以及与体液分析仪通信的治疗剂量系统，所述治疗剂量系统包括治疗剂量方案，并配置为确定输注液的推荐剂量，其中推荐剂量至少部分基于体液分析仪对分析物浓度和治疗剂量方案的一次或多次确定。
• Adjustable connector, improved fluid flow and reduced clotting risk
  申请人：OptiScan Biomedical Corporation

  公开号：US10028692B2

  公开（公告）日：2018-07-24

  Methods and systems for determining the concentration of one or more analytes from a sample such as blood or plasma are described. The systems described herein can be configured to withdraw a sample from a source of fluid, direct a first portion of the withdrawn sample to an analyte monitoring system and return a second portion of the sample. The analyte monitoring system can be connected to the fluid source via a connector that is configured to improve fluid flow and reduce blood clotting risk. These goals can be accomplished, for example, by employing coatings in or on a connector, positioning a resilient substance at or near the junction, by reducing dead space volume, by using resiliency to improve fit, by extending a portion of one connector to better mate with a portion of another connector, etc.

  本文描述了从血液或血浆等样本中确定一种或多种分析物浓度的方法和系统。所述系统可配置为从流体源提取样本，将提取样本的第一部分导入分析监测系统，并返回样本的第二部分。分析监测系统可通过连接器与流体源连接，连接器的配置可改善流体流动性并降低血液凝结风险。例如，可以通过在连接器内或连接器上使用涂层、在连接处或连接处附近放置弹性物质、减少死腔体积、利用弹性改善配合、延长一个连接器的一部分以更好地与另一个连接器的一部分配合等方式来实现这些目标。
• Fluid analysis system
  申请人：OptiScan Biomedical Corporation

  公开号：US10201303B2

  公开（公告）日：2019-02-12

  Systems and method are disclosed for determining a concentration of an analyte in a fluid (e.g., blood). The system can draw blood from a patient and deliver the blood to a sample cell. A particular component of the fluid (e.g., plasma) may be separated and/or positioned such that the concentration of the analyte is measured in the particular component of the fluid (e.g., plasma). The sample cell can include a sample container that has two window pieces. The system can have a fluid passage having a tip configured to mate with a multi-lumen catheter without leaking. The multi-lumen catheter can have proximal and distal ports. A fluid pressure system can be configured to periodically draw fluid from vasculature through a proximal intravascular opening and the proximal port while maintaining a low pressure and/or flow rate to thereby reduce risk of reversing the fluid flow in a vessel and drawing infusates upstream into another intravascular opening.

  本文公开了用于确定流体（如血液）中分析物浓度的系统和方法。该系统可以从病人身上抽取血液，并将血液输送到样品池。流体的特定成分（如血浆）可被分离和/或定位，以便在流体的特定成分（如血浆）中测量分析物的浓度。样品池可以包括一个具有两个窗口的样品容器。系统可以有一个流体通道，其顶端可以与多腔导管连接而不会泄漏。多腔导管可以具有近端和远端端口。流体压力系统可配置为周期性地通过近端血管内开口和近端端口从血管中抽取流体，同时保持较低的压力和/或流速，从而降低血管中流体流向逆转的风险，并将输液逆流到另一个血管内开口。
• Method and apparatus for analyte measurements using calibration sets
  申请人：Callicoat David N.

  公开号：US10475529B2

  公开（公告）日：2019-11-12

  Examples of methods and apparatus are described that permit an analyte concentration to be estimated from a measurement in the presence of compounds that interfere with the measurement. In one example, the method can reduce the error in the estimation of analyte concentration in the presence of interferents. The method can include the use of one or more calibration set to determine analyte concentration. From a sample measurement, each calibration set can be tested to determine if it is eligible to estimate the analyte concentration in the sample. An estimate of analyte concentration can then be produced, based at least in part on the eligible calibration sets and on the sample measurement. In some implementations, if no calibration sets are eligible, an action is taken such as not outputting an estimate, displaying an alarm or alert, or providing a notification.

  本文描述了一些方法和设备实例，这些方法和设备可以在存在干扰测量的化合物的情况下，通过测量估算出被分析物的浓度。在一个例子中，该方法可以减少在存在干扰物的情况下估计被分析物浓度的误差。该方法可包括使用一个或多个校准集来确定分析物浓度。根据样品测量结果，可对每个校准集进行测试，以确定其是否符合估计样品中分析物浓度的条件。然后，至少部分基于符合条件的校准集和样本测量结果，就能得出分析物浓度的估计值。在某些实施方案中，如果没有符合条件的校准集，则会采取相应措施，例如不输出估计值、显示警报或提示，或发出通知。